FDA’s new peptide panel includes industry-linked proponents, AP reports

The Food and Drug Administration has released the participant list for its upcoming advisory meeting on seven controversial peptide injections, and AP reports the roster includes several doctors, pharmacists and business operators with ties to the peptide market.

The new disclosure shifts attention from the question of whether the FDA will review the compounds to who will help shape that review. According to AP, the panel includes people who promote or profit from peptides, rather than a predominantly academic slate of experts.

The meeting is scheduled for July 23-24 and will consider whether restrictions on seven peptides should be eased: BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax and Epitalon.

The new roster

AP identified panelists including Dr. Haleem Mohammed, Dr. Gabriel Alizaidy and Tennessee state Sen. Bobby Harshbarger as having ties to peptide sales or promotion. Their inclusion has raised questions about conflict-of-interest standards and how the FDA selected the lineup.

The agency has not publicly explained the criteria behind the participant list, at least in the reporting cited by AP. That leaves open whether the roster reflects a deliberate shift in expertise, a search for practical market knowledge, or something in between.

The concern for critics is that the committee appears to be moving away from the more academic lineups that have typically populated FDA advisory discussions. Supporters of the panel’s composition could argue that people with direct experience in the market are better positioned to discuss how the products are actually used.

Why the meeting matters

The committee is expected to weigh whether the peptides should be allowed for compounding use in a range of conditions, including obesity, insomnia, wound healing and inflammatory diseases, according to earlier reporting from The Washington Post.

If the FDA eases restrictions, the effect could reach far beyond this one meeting. The Guardian reported that a looser approach could effectively legitimize a thriving gray market by allowing compounding pharmacies to prepare and fill prescriptions for the peptides.

That would matter to patients, clinics and pharmacy operators alike. A more permissive policy could expand access to products that are now sold through a patchwork of online vendors, wellness clinics and compounders operating in a regulatory gray zone.

The regulatory backdrop

The FDA has previously warned about safety concerns involving these peptides and about the limited evidence supporting their use, according to the reporting cited by AP and other outlets.

That caution sits uneasily beside the growing popularity of peptides in wellness and longevity circles, including among athletes, influencers and some supporters of the Make America Healthy Again movement. Many products are marketed online or through clinics, sometimes labeled for research use only.

Health Secretary Robert F. Kennedy Jr. has publicly described himself as a fan of peptides and has pushed for broader access, according to AP and prior reporting. That political backdrop has made the FDA review especially sensitive, because any change could be read as a broader signal about how the administration intends to handle unapproved therapies.

What happens next

The immediate questions are whether panelists will disclose conflicts in more detail, whether any of them will recuse themselves, and whether the FDA will explain why this roster was chosen.

The larger question is whether the committee’s eventual recommendation will change policy in a way that expands compounding for these drugs. If it does, the decision could reshape business models for compounding pharmacies and influence how the FDA approaches other unapproved therapies that have gained traction in the wellness market.

For now, the release of the participant list has made the July meeting more than a technical regulatory review. It is now also a test of the FDA’s credibility in overseeing a market where public health claims, commercial interests and political pressure overlap.